PubMed Health⌕ Search

Biomedical subjects

G D Perkin

Publications and source records attributed to G D Perkin.

At least 19 recordsLinked to original sources
PubMed1991

Optic neuritis.

Explore the source record for details and available documents.

Humans↗
PubMed1989

An analysis of 7836 successive new outpatient referrals.

An analysis has been performed of 7836 successive new outpatient referrals seen by one consultant neurologist. In approximately a quarter of the patients, a specific diagnosis was not possible. A further 30% of the total was accounted for by epilepsy, tension headache, cerebrovascular disease and migraine.

Ambulatory Care↗
PubMed1989

The association of hemifacial spasm and facial pain.

The recognition of an association between trigeminal neuralgia and ipsilateral hemifacial spasm has been delayed by confusion over the nomenclature of the two conditions. Three patients are presented who had facial pain associated with hemifacial spasm. The findings on investigation of these patients, and an analysis of the literature, suggests that the combination is almost inevitably associated with pathological processes in the posterior fossa, particularly anomalous, ectatic or aneurysmal blood vessels.

Facial Muscles↗
PubMed1989

Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS.

To compare the efficacy of high-dose intravenous methylprednisolone with intramuscular ACTH in the treatment of acute relapse in multiple sclerosis, we undertook a double-blind, randomized, controlled study involving 61 patients. There was a marked improvement in both groups in the course of the study, but no difference between them in either the rate of recovery or the final outcome. High-dose IV methylprednisolone is a safe alternative to ACTH in the management of acute relapse in MS.

Acute Disease↗
PubMed1987

A critique of steroid trials in multiple sclerosis.

A review has been performed of the trials of steroids in MS published between 1958 and 1970. None of the trials concerned with the long-term treatment of the disease, whether with ACTH or oral steroids, revealed any benefit. Some advantage of steroids over placebo in accelerating the recovery of acute exacerbations can be claimed, though in no study has the gain been substantial.

Adrenocorticotropic Hormone↗
PubMed1986

Multiple sclerosis: increased expression of interleukin-2 receptors on lymphocytes.

The percentage of interleukin-2-receptor-positive peripheral blood lymphocytes in MS patients was significantly higher in acute relapse than in remission or in controls. After stimulation by phytohemagglutinin, the expression of interleukin-2 receptor on peripheral blood lymphocytes of MS patients was within the range of healthy controls, implying no general impairment of receptor expression. These results confirm other evidence that there is a small population of activated T lymphocytes in acute relapse of MS.

Adult↗
PubMed1985

Prognosis in Guillain-Barré syndrome.

The case-records of 71 patients from previous therapeutic trials were used to determine features in clinical presentation that might be useful in predicting the outcome of the Guillain-Barré syndrome. The major features adversely affecting prognosis were severe maximum deficit requiring ventilation and failure to improve within 3 weeks of reaching peak deficit. The risk of poor outcome in a patient who required ventilation and failed to improve within 3 weeks was 86%.

Activities of Daily Living↗
PubMed1978

Controlled trial prednisolone in acute polyneuropathy.

In a multicentre, randomised trial of prednisolone in acute polyneuropathy of undetermined aetiology (Guillain-Barré syndrome), 21 patients were treated with prednisolone (60 mg daily for one week, 40 mg daily for four days, and then 30 mg daily for three days) and 19 did not have steroid treatment. Patients were graded on a six-point scale by one of two neurologists who had no knowledge of the treatment schedule. Reassessment at one, three, and twelve months consistently showed greater improvement in the control than the prednisolone group but the only statistically significant result was in the improvement at three months among patients entered to the trial within a week of onset of illness. The 6 control patients had improved by 2.5 +/- 0.43 grades by three months from entry to the trial whereas the 10 prednisolone patients had only improved by 0.9 +/- 0.46 grades (P less than 0.05). There was 1 death related to the polyneuropathy in each group, and 1 suicide in a control patient during convalescence. 6 prednisolone patients were left with considerable disability compared with 1 control patient. There were 3 relapses in the prednisolone group, but none in the control group. The results indicate that steroid treatment is not beneficial and can be detrimental in acute neuropathy of undetermined aetiology.

Acute Disease↗
PubMed1976

A trial of brolitene in the treatment of spasticity.

A new anti-spasticity agent, brolitene, has been assessed in patients with spasticity of spinal or cerebral origin. Twenty-seven patients were entered in a double-blind cross-over trial lasting 6 weeks, using a fixed dose of six tablets (1200 mg brolitene) per day. Clinical assessment failed to show any therapeutic effect in the seventeen patients completing the trial, except in one with multiple sclerosis. Ten patients had to be withdrawn from the trial, six while being treated with the active agent.

Adult↗
PubMed1976

Uhthoff's syndrome.

A total of 125 patients with a previous episode of optic neuritis was followed to assess the subsequent prevalence of transient visual blurring. 32.8 per cent developed this symptom and the precipitating factors were identified. No correlations were found between the development of the symptom and the parameters of optic nerve function studied.

Adult↗